- Organisation name (click for the website): Bio.be
- Contact person (click for the email): Julie De Wever, Head of Bio.be
- Head quarter country: Belgium
- Type of stakeholder: Medical laboratory
- Organisation size: Small (< 50 employees and ≤ € 10 m turnover)
- Market presence: European
- Overall description of the organisation: Bio.be is part of IPG Group (Institute for Pathology and Genetics Group), created in Belgium more than 60 years ago and composed of 3 entities:
– IPG (one of the eight centres of Genetics in Belgium);
– IPG Biobank;
– Bio.be.
Through its offering for testing and laboratory services in Anatomopathology, Cytogenetics and Molecular Biology, Bio.be delivers customizes biomarker solutions for precision medicine in different therapeutic area including oncology. The following are some of our key features:
– Multidisciplinary approach integrating pathology with molecular research, which is the necessary bridge between biology and medicine;
– High laboratory capabilities (350 000 tests/year) that serve R&D, validation, routine and medical diagnostic;
– Technical expertise > 63 years;
– NGS Platform with 14 sequencers;
– 25% resources are principal scientists and physicians (pathologists, geneticists and clinical biologists);
– Highest quality state-of-the-art techniques and services through a strong collaboration between our project managers, scientific expert and physicians. IPG Group certification: ISO 9001 and ISO 15189. - Areas of cooperation sought: Bio.be is looking for cooperation in bioinformatics analysis. Bio.be can offer web lab capacitites and the associated diagnostic expertise of the Institute of Pathology and Genetics, on the the eight Belgian Genetics Centre.
Matchmaking: find a partner!
Is your company interested in taking up the oncNGS PCP challenge? Now it’s time to look for potential partners!
These companies are interested in finding partners to create consortia and jointly participate in the oncNGS PCP tender. Check the information below.
- Organisation name (click for the website): IQVIA
- Contact person (click for the email): Bruno Denys, Associate Director Technology
- Head quarter country: Belux HQ of a multinational with HQ in USA
- Type of stakeholder: Research
- Organisation size: Large
- Market presence: International
- Overall description of the organisation: IQVIA is a world leader in using data, technology, advanced analytics and human expertise to help customers drive healthcare – and human health – forward. Together with the companies we serve, we are enabling a more modern, more effective and more efficient healthcare system, and creating breakthrough solutions that transform business and patient outcomes.
IQVIA is unlocking genomic data, at scale, while preserving privacy. Enabling a faster, more flexible, and less expensive approach for scientific enquiry into human biology, drug discovery and drug development.
With the IQVIA CORE, we bring innovation to the needs of today’s oncology development to help you focus on the patient, manage trial complexity, and increase predictability and speed.
IQVIA helps you:
– Integrate biomarker strategies, operations and partners from development plans through trial execution
– Design and execute adaptive and novel trial designs
– Use patient insights to improve trial design, speed recruitment and reduce patient burden
– Plan and execute cell and gene therapy programs with specialized expertise and resources
– Optimize development plans by applying real world and commercial insights in clinical strategies and forecasting scenarios
– Apply AI and machine learning to improve trial efficiency and patient safety
- Organisation name (click for the website): SeqOne Genomics
- Contact person (click for the email): Myriam Guiral, CCO
- Head quarter country: France
- Type of stakeholder: IT/Digital Health SME
- Organisation size: Small (< 50 employees and ≤ € 10 m turnover)
- Market presence: European
- Overall description of the organisation: SeqOne, a bioinformatics company based in Montpellier, develops cutting edge genomic analysis tools for NGS data interpretation for the diagnosis of constitutional, hereditary diseases and somatic diseases in the context of personalised medicine.
The SeqOne’ platform is an end-to-end solution with CE-IVD marking that covers the full analysis from FastQ file to final clinical report minimising human intervention to reduce turnaround time with the following key features:
– State-of-the-art bioinformatics capable of identifying all relevant variants, including challenging variants traditional bioinformatic tools struggle to isolate,
– An end-to-end solution that covers the full analysis from FastQ file to final clinical report including therapeutic recommendations and clinical trial associations, minimising human intervention to reduce turnaround time and manual inputs,
– A catalog of bioinformatic applications each designed for a specific medical need and capable of addressing both somatic and constitutional requirements
– Built-in quality control and certification support tools that ensure the quality and accuracy of your results while simplifying the lab certification process, and
– An easy-to-use interpretation interface that simplifies the task of biologists interpreting the data while giving them all the information they need to validate interpretations with confidence.
Our NGS interpretation platform is fully validated for tumor samples and can be « technically » used to analyse data from ctDNA. We are also finalizing our Virtual tumor board and collaborative interpretation tools. - Areas of cooperation sought: We are searching Wetlab partner/kit provider to do a bundle offer for the oncNGS challenge in order to finalize our calibration & validation of our tool in ctDNA and to validate our VTM at an European level.
- Organisation name (click for the website): Integrated DNA Technologies, Inc. (IDT)
- Contact person (click for the email): Anfisa Solovyeva, Territory Sales Manager NGS
- Head quarter country: Coralville, USA (European head facility in Leuven, Belgium)
- Type of stakeholder: Biotech company
- Organisation size: Large
- Market presence: International
- Overall description of the organisation: Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic research, biotechnology, medical diagnostics, and pharmaceutical development. The company’s primary business is the production of custom oligonucleotides for molecular biology and healthcare applications. IDT has developed proprietary technologies for genomics applications such as next generation sequencing (NGS), CRISPR genome editing, qPCR, and RNA interference. Through its GMP services, IDT manufactures products used in diagnostic tests for many forms of cancer and most inherited and infectious diseases. The company serves its customers through direct sales in many countries and a network of international distributors. IDT has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing facilities in San Diego, California, USA; Leuven, Belgium; and Singapore. The company has offices in Skokie, Illinois, USA; Glasgow, United Kingdom; Munich, Germany; and Baulkham Hills, Australia.
- Organisation name (click for the website): Agilent Technologies
- Contact person (click for the email): Céline Huynen, Account Manager Genomics
- Head quarter country: USA
- Type of stakeholder: Research
- Organisation size: Large
- Market presence: International
- Overall description of the organisation: Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give them the highest confidence in our solutions. In the field of diagnostics Agilent gives doctors a head start in the fight against cancer and other diseases. Our solutions help pathology laboratories deliver fast, accurate information to the doctors, hospitals and medical centers they serve. We help medical professionals make more accurate diagnoses so patients can receive the most effective therapies. Most life sciences and diagnostics research is done at top-tier universities, with funding from governments around the world. Agilent is helping these researchers learn more about cancer, cardiovascular diseases, diabetes, Alzheimer’s, Parkinson’s, autism and other ailments. Our instruments, software and sample preparation solutions help scientists conduct faster, more accurate research.
- Areas of cooperation sought:
What we may need:
– Access to clinical samples
– Content design
What we can offer: Expertise and capabilities in Biochemistries/QC/Automation/Distribution/Commercialization…
- Organisation name (click for the website): Fraunhofer Gesellschaft zur angewandten Forschung e.V.
- Contact person (click for the email): Bernhard Polzer, Head of Division Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Head quarter country: Germany
- Type of stakeholder: Research
- Organisation size: Large
- Market presence: International
- Overall description of the organisation: The Fraunhofer-Gesellschaft is the world’s leading applied research organization. With its focus on developing key technologies that are vital for the future and enabling the commercial exploitation of this work by business and industry, Fraunhofer plays a central role in the innovation process. The division Personalized Tumor Therapy in Regensburg, Germany is focusing on application of rare single cell analysis and liquid biopsy bridging the translational gap between technological applications and research on patient samples.
- Areas of cooperation sought: Our commitment is to bring liquid-biopsy and based workflows and single cell technology to clinical application and we are interested to support commercial partners with our expertise and R&D services in rare cell enrichment, isolation and molecular analysis.
- Organisation name (click for the website): pxlence
- Contact person (click for the email): Jo Vandesompele, CSO
- Head quarter country: Dendermonde, Belgium
- Type of stakeholder: medtech SME
- Organisation size: Micro (<10 employees and ≤ € 2 m turnover)
- Market presence: International
- Overall description of the organisation: pxlence bvba is a Ghent University spin-off company (2015) with best-in-class PCR assays for targeted resequencing of the entire human exome based on a predesigned database of 1 million PCR assays. The assays work on high-molecular weight DNA as well as FFPE DNA and cell-free DNA from liquid biopsies. The PCR assays are currently being used for NGS variant confirmation (singleplex) and for Human Sample ID Kit based DNA authentication (multiplex, 44 SNPS). With a VLAIO grant, we are currently developing PCR technology for multiplex based ctDNA sequencing of a) entire genes or hotspots, or b) private mutations for monitoring and MRD.
- Areas of cooperation sought: pxlence is looking for potential partners in the frame of:
a) amplicon sequencing data-analysis, with experience in UMI-based error correction (ideally on cell-free DNA), variant calling, variant interpretation, and reporting, ideally via a cloud/web solution;
b) and/or accredited laboratories that can validate our kit according to ISO or equivalent guidelines and offer it as a service.
- Organisation name (click for the website): Phenosystems SA
- Contact person (click for the email): David Atlan, CEO
- Head quarter country: Belgium – Switzerland
- Type of stakeholder: IT/Digital Health SME
- Organisation size: Micro (<10 employees and ≤ € 2 m turnover)
- Market presence: European
- Overall description of the organisation: Phenosystems develops software in the field of molecular genetics and genomics. Our products are targeted for the biologist, or MD working on DNA sequences, whether it is human, viral or bacterial DNA, as well as for the biologists working in the veterinary field. We have successfully participated in various EU funded research projects in FP6 (Eurogentest Network of Excellence) and FP7 (capHIV, NMDchip, Gen2Phen) as well as a Eureka funded project (Gennet).
Our expertise encompasses:
– End-user oriented software development (GUI)
– High performance and Cloud computing
– Applications for molecular genetics and genomics, understanding medical work processes.
– Experience in EU projects up to Work-package leader.
Relevant for OncNGS is our software GensearchNGS which is already in use in accredited diagnostics and pathology labs in Europe and used among others for the detection of genomic variants in cancer NGS - Areas of cooperation sought: We are specialised in software development and are looking potentially for partners with competences in dedicated hardware solutions for acceleration of computation problems such as aligning genome data as well as secure data storage and sharing solutions.